Table 2 Study outcomes pre- and post-intervention
|  | Control (n = 23) | Pharmacist MTM (n = 24) |  | |||
|---|---|---|---|---|---|---|
| Â | Baseline | End-of-trial | Baseline | End-of-trial | OR (95Â % CI) | P value |
Proteinuria screeninga | 14 (60.9 %) | 17 (73.9 %) | 10 (41.7 %) | 21 (87.5 %) | Entire population: 2.6 (0.5–14.0) Previously unscreened subgroup:7.3 (0.96–56.3) | Entire population: 0.3 Previously unscreened subgroup: 0.05 |
Lipid screening | 23 (100Â %) | 23 (100Â %) | 21 (87.5Â %) | 24 (100Â %) | N/A | N/A |
Treatment with statin | 16 (69.6 %) | 17 (73.9 %) | 13 (54.2 %) | 12 (50.0 %) | 0.4 (0.1–1.3) | 0.1 |
Achieved BP goal | 9 (39.1 %) | 13 (56.5 %) | 10 (41.7 %) | 13 (54.2 %) | 0.9 (0.3–3.0) | 0.9 |